Description

GRAVITOR SR 180 MG

Indications

GRAVITOR SR 180 MG is primarily indicated for the management of various types of anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder. It may also be prescribed for the treatment of depressive disorders, particularly when symptoms of anxiety are present. The extended-release formulation allows for once-daily dosing, providing a convenient option for patients requiring long-term management of their symptoms.

Mechanism of Action

The active ingredient in GRAVITOR SR 180 MG is venlafaxine, which is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). Venlafaxine works by inhibiting the reuptake of serotonin and norepinephrine in the synaptic cleft, thereby increasing the levels of these neurotransmitters in the brain. This dual action is believed to contribute to its efficacy in alleviating symptoms of anxiety and depression. The extended-release formulation ensures a steady release of the medication, maintaining therapeutic levels throughout the day.

Pharmacological Properties

GRAVITOR SR 180 MG exhibits a unique pharmacokinetic profile characterized by its extended-release formulation. After oral administration, venlafaxine is rapidly absorbed, with peak plasma concentrations typically occurring within 4 to 5 hours. The bioavailability of venlafaxine is approximately 45%, and it is extensively metabolized in the liver to its active metabolite, O-desmethylvenlafaxine (ODV). The elimination half-life of venlafaxine is about 5 hours, while ODV has a longer half-life of approximately 11 hours, allowing for sustained therapeutic effects. The drug is primarily excreted in the urine, with about 87% of the dose eliminated as metabolites.

Contraindications

GRAVITOR SR 180 MG is contraindicated in patients with a known hypersensitivity to venlafaxine or any of its components. It should not be used in conjunction with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI, as this can lead to serious and potentially fatal interactions. Additionally, the medication is contraindicated in patients with uncontrolled narrow-angle glaucoma, as it may exacerbate this condition.

Side Effects

Common side effects associated with GRAVITOR SR 180 MG include nausea, dizziness, dry mouth, insomnia, and constipation. These side effects are generally mild to moderate in severity and may diminish over time as the body adjusts to the medication. However, some patients may experience more serious side effects, such as increased blood pressure, serotonin syndrome, or withdrawal symptoms upon discontinuation. It is essential for patients to report any unusual or severe side effects to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of GRAVITOR SR 180 MG is typically 75 mg once daily, which may be adjusted based on individual patient response and tolerability. The maximum recommended dose is 225 mg per day. It is advisable to take the medication with food to enhance absorption and reduce gastrointestinal side effects. Patients should swallow the capsule whole and not crush or chew it, as this may alter the release mechanism and lead to increased side effects.

Interactions

GRAVITOR SR 180 MG may interact with several other medications, potentially increasing the risk of adverse effects. Co-administration with other serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs), triptans, or certain herbal supplements like St. John’s Wort, may increase the risk of serotonin syndrome. Additionally, medications that affect hepatic enzymes, particularly CYP2D6 inhibitors, can alter venlafaxine metabolism, necessitating dose adjustments. It is crucial for patients to inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Prior to initiating treatment with GRAVITOR SR 180 MG, a thorough assessment of the patient’s medical history is essential. Caution should be exercised in patients with a history of hypertension, as venlafaxine can increase blood pressure. Regular monitoring of blood pressure is recommended during treatment. Patients with a history of seizures, bipolar disorder, or those at risk of suicidal ideation should be closely monitored. It is also important to consider the risk of withdrawal symptoms; therefore, tapering the dose gradually is recommended when discontinuing the medication.

Clinical Studies

Clinical studies have demonstrated the efficacy of GRAVITOR SR 180 MG in treating anxiety and depressive disorders. In randomized controlled trials, patients receiving venlafaxine showed significant improvements in anxiety symptoms compared to placebo. The studies indicated that the extended-release formulation provided sustained relief with a favorable tolerability profile. Additionally, long-term studies have suggested that venlafaxine can effectively manage symptoms over extended periods, making it a viable option for chronic anxiety and depression.

Conclusion

GRAVITOR SR 180 MG is a well-established medication for the treatment of anxiety and depressive disorders. Its mechanism of action as a serotonin-norepinephrine reuptake inhibitor provides a dual approach to symptom management, making it effective for a broad range of patients. While generally well-tolerated, it is essential for patients to be aware of potential side effects and interactions. Regular follow-up and communication with healthcare providers are crucial for optimizing treatment outcomes and ensuring patient safety.